184 related articles for article (PubMed ID: 9052903)
21. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells.
Eckols K; Bymaster FP; Mitch CH; Shannon HE; Ward JS; DeLapp NW
Life Sci; 1995; 57(12):1183-90. PubMed ID: 7674807
[TBL] [Abstract][Full Text] [Related]
22. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
[TBL] [Abstract][Full Text] [Related]
23. The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.
Sramek JJ; Cutler NR; Hurley DJ; Seifert RD
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jan; 19(1):85-91. PubMed ID: 7535938
[TBL] [Abstract][Full Text] [Related]
24. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
Bymaster FP; Carter PA; Peters SC; Zhang W; Ward JS; Mitch CH; Calligaro DO; Whitesitt CA; DeLapp N; Shannon HE; Rimvall K; Jeppesen L; Sheardown MJ; Fink-Jensen A; Sauerberg P
Brain Res; 1998 Jun; 795(1-2):179-90. PubMed ID: 9622623
[TBL] [Abstract][Full Text] [Related]
25. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline.
Frederick Bd; Satlin A; Wald LL; Hennen J; Bodick N; Renshaw PF
Am J Geriatr Psychiatry; 2002; 10(1):81-8. PubMed ID: 11790638
[TBL] [Abstract][Full Text] [Related]
26. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
[TBL] [Abstract][Full Text] [Related]
27. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
28. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
29. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
Stengel PW; Cohen ML
J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
[TBL] [Abstract][Full Text] [Related]
30. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
31. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
Vardigan JD; Cannon CE; Puri V; Dancho M; Koser A; Wittmann M; Kuduk SD; Renger JJ; Uslaner JM
Psychopharmacology (Berl); 2015 Jun; 232(11):1859-66. PubMed ID: 25491927
[TBL] [Abstract][Full Text] [Related]
32. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Messer WS
J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
[TBL] [Abstract][Full Text] [Related]
33. Novel persistent activation of muscarinic M1 receptors by xanomeline.
Christopoulos A; El-Fakahany EE
Eur J Pharmacol; 1997 Sep; 334(1):R3-4. PubMed ID: 9346340
[TBL] [Abstract][Full Text] [Related]
34. The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.
Montani C; Canella C; Schwarz AJ; Li J; Gilmour G; Galbusera A; Wafford K; Gutierrez-Barragan D; McCarthy A; Shaw D; Knitowski K; McKinzie D; Gozzi A; Felder C
Neuropsychopharmacology; 2021 May; 46(6):1194-1206. PubMed ID: 33342996
[TBL] [Abstract][Full Text] [Related]
35. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor.
Jakubík J; Tucek S; El-Fakahany EE
J Pharmacol Exp Ther; 2002 Jun; 301(3):1033-41. PubMed ID: 12023535
[TBL] [Abstract][Full Text] [Related]
36. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
38. Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia.
Pomara N
Am J Psychiatry; 2009 Jan; 166(1):111; author reply 111-3. PubMed ID: 19122018
[No Abstract] [Full Text] [Related]
39. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease.
Clader JW; Wang Y
Curr Pharm Des; 2005; 11(26):3353-61. PubMed ID: 16250841
[TBL] [Abstract][Full Text] [Related]
40. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
Bymaster FP; Wong DT; Mitch CH; Ward JS; Calligaro DO; Schoepp DD; Shannon HE; Sheardown MJ; Olesen PH; Suzdak PD; Swedberg MD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):282-9. PubMed ID: 7909558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
